Meglumine antimoniate description

Revision as of 03:39, 7 January 2014 by Gerald Chi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Meglumine Antimoniate
GLUCANTIM® WHO Prescribing Information
Description
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Description

Pentavalent antimony compounds with leishmanicidal activity, but which are not effective against free flagellated forms in vitro. It is uncertain whether they have selective activity against intracellular forms, or whether small amounts are converted intracellularly into a potent trivalent inhibitor of the parasite’s glycolytic enzymes.

Since they are poorly absorbed and highly irritant to the gastrointestinal tract they must be administered parenterally or by local injection. Over 80% of the dose is excreted unchanged in the urine within 6 hours.[1]

References

  1. "WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate".

Adapted from the FDA Package Insert.